Efficacy and safety of pamidronate in children with vitamin D intoxication

Basit Öğe Kaydı
dc.authoridKara, Cengiz/0000-0002-8989-560X;
dc.contributor.authorKara, Cengiz
dc.contributor.authorCetinkaya, Semra
dc.contributor.authorGunduz, Suzan
dc.contributor.authorYilmaz, Gulay Can
dc.contributor.authorAycan, Zehra
dc.contributor.authorAydin, Murat
dc.date.accessioned2025-10-24T18:09:23Z
dc.date.available2025-10-24T18:09:23Z
dc.date.issued2016
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackgroundBisphosphonates are used in the treatment of vitamin D intoxication (VDI) after failure of conventional therapy including prednisolone. Safety concerns restrict the use of bisphosphonates from being used as first-line therapy for VDI in children. The aim of this study was to evaluate the efficacy and safety of pamidronate in comparison with prednisolone in children with VDI. MethodsWe reviewed the hospital records of children consecutively diagnosed with VDI at two medical centers in a 15year period. ResultsThe subjects consisted of 21 children (age, 0.3-4.2years) who were treated with prednisolone and/or bisphosphonates. Pamidronate (n=18) or alendronate (n=3) was used in six patients after unsuccessful prednisolone treatment, and in 15 patients from baseline. Initial serum calcium and 25-hydroxyvitamin D were 16.11.9mg/dL and 493 +/- 219ng/mL, respectively. The median time to reach normocalcemia in the pamidronate, alendronate and prednisolone groups was 3days (range, 2-12days), 4days (range, 3-6days) and 17days (range, 12-26days), respectively (P=0.013). The pamidronate group had a fivefold shorter hospital stay than the prednisolone group. Three patients initially treated with prednisolone developed nephrocalcinosis but this did not occur in any patient treated with bisphosphonates from baseline. Apart from transient fever and moderate hypophosphatemia, no side-effect of bisphosphonate treatment was observed. ConclusionsPamidronate is efficient and safe for the treatment of VDI in children. Pamidronate use significantly shortens the duration of treatment, and thereby may prevent the development of nephrocalcinosis. Instead of prednisolone, pamidronate should be used together with hydration and furosemide as the first-line therapy for VDI.
dc.identifier.doi10.1111/ped.12875
dc.identifier.endpage568
dc.identifier.issn1328-8067
dc.identifier.issn1442-200X
dc.identifier.issue7
dc.identifier.pmid26646324
dc.identifier.scopus2-s2.0-84979679138
dc.identifier.scopusqualityQ3
dc.identifier.startpage562
dc.identifier.urihttps://doi.org/10.1111/ped.12875
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3618
dc.identifier.volume58
dc.identifier.wosWOS:000380696200003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-Blackwell
dc.relation.ispartofPediatrics International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20251023
dc.subjectbisphosphonate; glucocorticoid; hypercalcemia; nephrocalcinosis; vitamin D intoxication
dc.titleEfficacy and safety of pamidronate in children with vitamin D intoxication
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu